Media
Biogen, Eisai's lecanemab gets Alzheimer's nod, but how successful it will be is uncertain
Dr. Karlawish says APOE4 testing should part of the process when determining whether or not to prescribe Leqembi (lecanemab) to an individual.
Lecanemab and the state of Alzheimer's treatment research - SciLine
Dr. Karlawish answers common questions about the recently approved Alzheimer's drug Leqembi (lecanemab).
Revised clinical trial form for Alzheimer’s antibody warned of fatal brain bleeds
Dr. Karlawish weighs in on the safety considerations of Leqembi (lecanemab).
New Alzheimer's Drug Brings Hope—and Tough Choices for Patients, Caregivers
What’s the difference between Leqembi (lecanemab) and its predecessor Aduhelm? Dr. Karlawish explains the differences and the safety concerns of Leqembi.
Is it time for geriatricians to get on board with lecanemab?
Drs. Karlawish and Ken Covinsky discuss lecanemab and how geriatricians can prepare to talk about the drug with their patients.
As some hail new antibody treatment for Alzheimer’s, safety and benefit questions persist
Dr. Karlawish says the Alzheimer’s drug lecanemab is “truly a breakthrough.”
Second Death Tied to Experimental Alzheimer’s Treatment
Dr. Karlawish comments on recent results published on the experimental drug lecanemab.
Penn Collaboratory on Healthy Aging funds 12 new projects with over $2.1 million in grants
“We are excited to provide a supportive environment to deploy and test cutting-edge technologies,” said Dr. Karlawish.
What’s It Like to be a Person Living with Dementia?
Dr. Karlawish presents at the University of Utah School of Medicine Grand Rounds.
Dare We Say Consensus Achieved: Lecanemab Slows the Disease
“The risk/benefit assessment is an ethically challenging Gordian knot. FDA and CMS should collaborate to assure this complicated drug’s transition from research into practice is net beneficial,” Dr. Karlawish commented.
Dr. Jason Karlawish talks new Alzheimer's drug
What's next for the Alzheimer's drug lecanemab? PMC Co-Director Dr. Jason Karlawish offers his insights to BBC and calls the recent research on lecanemab a "breakthrough clinically and scientifically."
WHYY Regional Roundup, lecanemab
Dr. Karlawish answers common questions about lecanemab, such as its benefits, risks, and challenges.
THE CASE FOR DISCLOSING BIOMARKER RESULTS TO ALZHEIMER’S RESEARCH PARTICIPANTS
Drs. Karlawish and Joshua Grill discuss the ethics of disclosing biomarker test results to Alzheimer’s disease research participants.
Evaluating seniors for their capability to make sound financial decisions
Drs. Karlawish and Mark Lachs develop a new training program called the Interview for Decisional Abilities (IDA).
How Will Alzheimer’s Trials, Treatment Change in 2023 and Beyond?
With Alzheimer's drug lecanemab on the horizon, dementia experts like Dr. Karlawish consider how clinical practice and research may be transformed.
Don't be so quick to blame aches and pains on getting older
Before writing off an ache or pain as age-related, Drs. Karlawish and Jeffrey Millstein say to ask yourself these three questions.
The curious case of the man with a hole in his stomach
Dr. Karlawish narrates the true tale from his book “Open Wound: The Tragic Obsession Dr. William Beaumont” of a man who was shot in the stomach and a doctor obsessed with experimenting on the injury.
Alzheimer’s drug slows cognitive decline, companies announce
Dr. Karlawish responds to the report that the experimental drug lecanemab helped slow cognitive decline in people living with Alzheimer’s.
Restoring Trust in the FDA
Dr. Karlawish and fellow panelists explore recent issues and controversies surrounding the U.S. Food and Drug Administration.
The life and legacy of Hilda Pridgeon
In this mini documentary, Dr. Karlawish tells the courageous story of Hilda Pridgeon, who co-founded the organization that would become the Alzheimer’s Association.
Another prospect for an Alzheimer's drug renews cost concerns
"If what they report is all proper and true and valid ... and holds up to scrutiny, we have an effective treatment for Alzheimer's disease," Dr. Karlawish said.
Alzheimer’s Disease Podcast
In this six-part podcast series, PMC Co-Director Dr. Jason Karlawish dives into Alzheimer's disease (AD) diagnostics, interventions for AD, and caring for someone living with AD.
Elder Justice Decision-Making Capacity Symposium
Dr. Karlawish speaks about advances in brain-aging research and its relevance for decision-making.
How to Detect and Talk to Patients and Their Families About Financial Scams
“You may lose your wealth and not be able to afford to take care of the very disease that's causing you to have problems that have made you a victim of scams,” said Jason Karlawish
Sizing Up the Decisions of Older Adults
Dr. Karlawish and Dr. Mark Lachs developed the Interview for Decisional Abilities (IDA) — a tool that can help determine whether or not an adult has the capacity to make decisions about their medical care, living conditions, and finances.
Can our smart speakers help detect Dementia or Alzheimer’s?
"It's only a matter of time," said Dr. Karlawish until patients book doctor visits because smart technologies detected signs of cognitive problems.
Alzheimer’s Patients Now Less Likely to Receive Biogen’s Aduhelm Treatment
"We're back to where we should be, which is we need to study this drug [Aduhelm] to establish whether in fact it slows the progression of disease," said Dr. Karlawish.
Dementia expert says evidence behind Biogen Alzheimer’s drug ‘wasn’t sufficient’ for FDA approval
Dementia expert Dr. Jason Karlawish told CNBC he’s skeptical of the Food and Drug Administration’s approval of Biogen’s Alzheimer’s disease drug, Aduhelm, saying “the evidence to approve the drug wasn’t sufficient.”
Penn researchers study a phenomenon that makes them question what we know about dementia
Dr. Karlawish and his lab, the Penn Program on Precision Medicine for the Brain (P3MB), are studying the mysterious, yet seemingly not uncommon, phenomenon “paradoxical lucidity.”
Alzheimer’s Disease from the Inside Out
“Stigma haunts Alzheimer’s like ghosts on Halloween,” said Dr. Karlawish on the podcast Science Rehashed.
New project to study the financial symptoms of Alzheimer’s
Dr. Karlawish and Dr. Lauren Hersch Nicholas are collaborating to test unique financial symptoms of Alzheimer’s disease and related dementias before diagnosis in credit data and Medicare claims.
In Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug
“The revision of this label is yet another piece of evidence that should cause the American public to be concerned about how FDA is practicing its regulatory science,” Dr. Jason Karlawish told the New York Times.
In The Problem of Alzheimer’s, Board Member Jason Karlawish Analyzes the Past and Future of Treatment for Alzheimer’s Disease
“The idea of Alzheimer’s disease as a crisis is not simply because there’s many older adults. It’s a crisis because of a host of social and cultural and political events – a humanitarian problem.” — Jason Karlawish
Bioethics Panel Discusses Smart Device Disease Diagnosis
In a panel discussion, Dr. Karlawish explored the ethical implications of diagnosing diseases like Alzheimer’s using smart technologies.
Alzheimer’s Drug Approval Sparks a Firestorm
“When I talk to patients about aducanumab, I include a narrative of the events that led to its approval. People need to understand where something comes from," said Dr. Karlawish.
Jason Karlawish on CNBC
Dr. Karlawish joins The News with Shepard Smith to discuss a German study showing that mental processing speed remains almost constant until age 60.
BREAKING DOWN MEDICARE’S PROPOSED DECISION ON ADUCANUMAB AND MONOCLONAL ANTIBODY TREATMENTS
Dr. Karlawish shares his reaction to the CMS proposal of the coverage of Aduhelm and discusses how this coverage policy could impact the development of other Alzheimer’s disease treatments in the future.
The Aduhelm Problem: Greenwall Faculty Scholars Weigh in on New Alzheimer’s Treatment
Dr. Karlawish and his colleagues are recognized for being "front and center" in critically thinking about Aduhelm and its controversies on a national level.
Reframing Dementia and Caregiving for the Future
The stigma of dementia, lack of long-term care infrastructure, and more prevents patients and caregivers from receiving the supports and care they need argues Dr. Karlawish on the Elevate Elder Care podcast.
The best books to make sense of what’s Alzheimer’s disease, dementia, and how to live with them (as either patient or caregiver, or both)
Find out the top five books Dr. Karlawish recommends for understanding Alzheimer’s, dementia, and how to live with them.
CMS Plans to limit Aduhelm covergae to Clinical trials
“The CMS did the right thing.” Dr. Karlawish explains why the Centers for Medicare and Medicaid Services (CMS) are on the right track with their proposal for the coverage of Aduhelm.
Medicare proposes covering expensive drug for early-stage Alzheimer’s
“FDA made a mistake with its accelerated approval. Most of the field has arrived at the conclusion. So in a sense, CMS is redressing that," Dr. Karlawish told The Washington Post.
Could the FDA’s Approval of a New Drug to Treat Alzheimer’s Disease do More Harm than good?
Dr. Karlawish discusses why the FDA's decision to approve aducanumab is so controversial and what the decision means for the future of AD clinical trials.
New Penn Colloboratory Aims to Improve Care for Older Adults
Dr. Karlawish will co-lead the Penn Artificial Intelligence and Technology Collaboratory for Healthy Aging (PennAITech).